Bacteria Detection Time Cut From Days to Minutes

HUBBARD, Ohio, Feb. 9, 2012 /PRNewswire/ -- NanoLogix (PINK SHEETS: NNLX), an innovator in rapid diagnostics, today released a comprehensive operations summary that revealed an exponential drop in detection and diagnostic times for active-threat bacteria and amoeba. This development is projected to provide reliable detection, ease of use, and the ability to identify live active-threat bacteria and differentiate from non-threat bacteria, faster and at lower cost than other technologies.

In recent third-party tests, two of NanoLogix's products, the BioNanoPore (BNP) and BioNanoFilter (BNF), provided diagnostic results 4 to 20 times faster than standard tests. Group B Streptococcus, a threat during pregnancy, took an hour or less rather than the standard 48-72 hours. Tuberculosis detection was reduced from weeks to 4 days.

These details are included in today's comprehensive summary of NanoLogix business operations, which covers technology advances, partnership collaborations, preparations for FDA approvals, media coverage, financial information and the company's new R&D laboratory.

To view the NanoLogix Company Summary, please visit:
http://nanologix.com/news/2011_company_update.html

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.

Patents pending and granted to NanoLogix can be used in the areas of clinical diagnostics, applied microbiology, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.

For more information visit www.nanologix.com.

Media Contact:
Lisa Ann Pinkerton
650-288-1824
[email protected]

Investor Contact:
Carol Surrena
NanoLogix, Inc.
330-534-0800
[email protected]

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

SOURCE NanoLogix, Inc.